Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK

X. G. Zhu, G. H. Greeley, B. G. Lewis, P. Lilja, J. C. Thompson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The purpose of this study, in part, was to determine the ability of cholecystokinin (CCK-33/39 and CCK-8) to penetrate the blood cerebrospinal fluid (CSF) barrier in dogs by measuring these forms of CCK in plasma and in CSF. In addition, the effectiveness of centrally administered bombesin in releasing brain CCK-33/39 and CCK-8 was evaluated. Six groups of five dogs each were studied. Each group received one of the following: (1) intravenous infusion of CCK-33/39 (1.3 μg/kg/hr); (2) intravenous infusion of CCK-8 (0.4 μg/kg/hr); (3) intrathecal infusion of CCK-33/39 (1.3 μg/kg/hr); (4) intrathecal infusion of CCK-8 (0.5 μg/kg/hr); (5) intravenous infusion of bombesin (1 μg/kg/hr); and (6) intrathecal infusion of bombesin (1 μg/kg/hr). Plasma concentrations of CCK-33/39 significantly increased during intravenous infusion of CCK-33/39 (from basal of 84±8 to 142±2 pg/ml) or bombesin (from basal of 78±13 to 325±87 pg/ml); however, CSF perfusate concentrations of CCK-33/39 did not increase. CCK-33/39 levels of the CSF perfusate increased significantly (P<.05) from 211±84 to 9,873±3,368 pg/ml during intrathecal infusion of CCK-33/39, but failed to rise simultaneously in the systemic circulation. Similarly, intravenous infusion of CCK-8 caused a fivefold elevation in plasma CCK-8 levels and no change in CSF perfusate levels of CCK-8; moreover, intrathecal infucsion of CCK-8 failed to elevate peripheral CCK-8 levels, despite CSF perfusate CCK-8 levels of 92,300±18,598 pg/ml. Intrathecal concentrations of neither CCK-33 nor CCK-8 were affected by intravenous or intrathecal administration of bombesin. We conclude that (1) CCK-33/39 and CCK-8 do not penetrate the blood-cerebrospinal fluid barrier in dogs, and (2) centrally administered bombesin is ineffective in causing release of cholecystokinin from brain tissue into the CSF.

Original languageEnglish (US)
Pages (from-to)393-403
Number of pages11
JournalJournal of Neuroscience Research
Volume15
Issue number3
StatePublished - 1986

Fingerprint

Bombesin
Sincalide
Cholecystokinin
Cerebrospinal Fluid
Brain
Intravenous Infusions
Dogs
cholecystokinin 39

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Zhu, X. G., Greeley, G. H., Lewis, B. G., Lilja, P., & Thompson, J. C. (1986). Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK. Journal of Neuroscience Research, 15(3), 393-403.

Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK. / Zhu, X. G.; Greeley, G. H.; Lewis, B. G.; Lilja, P.; Thompson, J. C.

In: Journal of Neuroscience Research, Vol. 15, No. 3, 1986, p. 393-403.

Research output: Contribution to journalArticle

Zhu, XG, Greeley, GH, Lewis, BG, Lilja, P & Thompson, JC 1986, 'Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK', Journal of Neuroscience Research, vol. 15, no. 3, pp. 393-403.
Zhu, X. G. ; Greeley, G. H. ; Lewis, B. G. ; Lilja, P. ; Thompson, J. C. / Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK. In: Journal of Neuroscience Research. 1986 ; Vol. 15, No. 3. pp. 393-403.
@article{596636ff22af4bc2a4fdc89548b3b91a,
title = "Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK",
abstract = "The purpose of this study, in part, was to determine the ability of cholecystokinin (CCK-33/39 and CCK-8) to penetrate the blood cerebrospinal fluid (CSF) barrier in dogs by measuring these forms of CCK in plasma and in CSF. In addition, the effectiveness of centrally administered bombesin in releasing brain CCK-33/39 and CCK-8 was evaluated. Six groups of five dogs each were studied. Each group received one of the following: (1) intravenous infusion of CCK-33/39 (1.3 μg/kg/hr); (2) intravenous infusion of CCK-8 (0.4 μg/kg/hr); (3) intrathecal infusion of CCK-33/39 (1.3 μg/kg/hr); (4) intrathecal infusion of CCK-8 (0.5 μg/kg/hr); (5) intravenous infusion of bombesin (1 μg/kg/hr); and (6) intrathecal infusion of bombesin (1 μg/kg/hr). Plasma concentrations of CCK-33/39 significantly increased during intravenous infusion of CCK-33/39 (from basal of 84±8 to 142±2 pg/ml) or bombesin (from basal of 78±13 to 325±87 pg/ml); however, CSF perfusate concentrations of CCK-33/39 did not increase. CCK-33/39 levels of the CSF perfusate increased significantly (P<.05) from 211±84 to 9,873±3,368 pg/ml during intrathecal infusion of CCK-33/39, but failed to rise simultaneously in the systemic circulation. Similarly, intravenous infusion of CCK-8 caused a fivefold elevation in plasma CCK-8 levels and no change in CSF perfusate levels of CCK-8; moreover, intrathecal infucsion of CCK-8 failed to elevate peripheral CCK-8 levels, despite CSF perfusate CCK-8 levels of 92,300±18,598 pg/ml. Intrathecal concentrations of neither CCK-33 nor CCK-8 were affected by intravenous or intrathecal administration of bombesin. We conclude that (1) CCK-33/39 and CCK-8 do not penetrate the blood-cerebrospinal fluid barrier in dogs, and (2) centrally administered bombesin is ineffective in causing release of cholecystokinin from brain tissue into the CSF.",
author = "Zhu, {X. G.} and Greeley, {G. H.} and Lewis, {B. G.} and P. Lilja and Thompson, {J. C.}",
year = "1986",
language = "English (US)",
volume = "15",
pages = "393--403",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK

AU - Zhu, X. G.

AU - Greeley, G. H.

AU - Lewis, B. G.

AU - Lilja, P.

AU - Thompson, J. C.

PY - 1986

Y1 - 1986

N2 - The purpose of this study, in part, was to determine the ability of cholecystokinin (CCK-33/39 and CCK-8) to penetrate the blood cerebrospinal fluid (CSF) barrier in dogs by measuring these forms of CCK in plasma and in CSF. In addition, the effectiveness of centrally administered bombesin in releasing brain CCK-33/39 and CCK-8 was evaluated. Six groups of five dogs each were studied. Each group received one of the following: (1) intravenous infusion of CCK-33/39 (1.3 μg/kg/hr); (2) intravenous infusion of CCK-8 (0.4 μg/kg/hr); (3) intrathecal infusion of CCK-33/39 (1.3 μg/kg/hr); (4) intrathecal infusion of CCK-8 (0.5 μg/kg/hr); (5) intravenous infusion of bombesin (1 μg/kg/hr); and (6) intrathecal infusion of bombesin (1 μg/kg/hr). Plasma concentrations of CCK-33/39 significantly increased during intravenous infusion of CCK-33/39 (from basal of 84±8 to 142±2 pg/ml) or bombesin (from basal of 78±13 to 325±87 pg/ml); however, CSF perfusate concentrations of CCK-33/39 did not increase. CCK-33/39 levels of the CSF perfusate increased significantly (P<.05) from 211±84 to 9,873±3,368 pg/ml during intrathecal infusion of CCK-33/39, but failed to rise simultaneously in the systemic circulation. Similarly, intravenous infusion of CCK-8 caused a fivefold elevation in plasma CCK-8 levels and no change in CSF perfusate levels of CCK-8; moreover, intrathecal infucsion of CCK-8 failed to elevate peripheral CCK-8 levels, despite CSF perfusate CCK-8 levels of 92,300±18,598 pg/ml. Intrathecal concentrations of neither CCK-33 nor CCK-8 were affected by intravenous or intrathecal administration of bombesin. We conclude that (1) CCK-33/39 and CCK-8 do not penetrate the blood-cerebrospinal fluid barrier in dogs, and (2) centrally administered bombesin is ineffective in causing release of cholecystokinin from brain tissue into the CSF.

AB - The purpose of this study, in part, was to determine the ability of cholecystokinin (CCK-33/39 and CCK-8) to penetrate the blood cerebrospinal fluid (CSF) barrier in dogs by measuring these forms of CCK in plasma and in CSF. In addition, the effectiveness of centrally administered bombesin in releasing brain CCK-33/39 and CCK-8 was evaluated. Six groups of five dogs each were studied. Each group received one of the following: (1) intravenous infusion of CCK-33/39 (1.3 μg/kg/hr); (2) intravenous infusion of CCK-8 (0.4 μg/kg/hr); (3) intrathecal infusion of CCK-33/39 (1.3 μg/kg/hr); (4) intrathecal infusion of CCK-8 (0.5 μg/kg/hr); (5) intravenous infusion of bombesin (1 μg/kg/hr); and (6) intrathecal infusion of bombesin (1 μg/kg/hr). Plasma concentrations of CCK-33/39 significantly increased during intravenous infusion of CCK-33/39 (from basal of 84±8 to 142±2 pg/ml) or bombesin (from basal of 78±13 to 325±87 pg/ml); however, CSF perfusate concentrations of CCK-33/39 did not increase. CCK-33/39 levels of the CSF perfusate increased significantly (P<.05) from 211±84 to 9,873±3,368 pg/ml during intrathecal infusion of CCK-33/39, but failed to rise simultaneously in the systemic circulation. Similarly, intravenous infusion of CCK-8 caused a fivefold elevation in plasma CCK-8 levels and no change in CSF perfusate levels of CCK-8; moreover, intrathecal infucsion of CCK-8 failed to elevate peripheral CCK-8 levels, despite CSF perfusate CCK-8 levels of 92,300±18,598 pg/ml. Intrathecal concentrations of neither CCK-33 nor CCK-8 were affected by intravenous or intrathecal administration of bombesin. We conclude that (1) CCK-33/39 and CCK-8 do not penetrate the blood-cerebrospinal fluid barrier in dogs, and (2) centrally administered bombesin is ineffective in causing release of cholecystokinin from brain tissue into the CSF.

UR - http://www.scopus.com/inward/record.url?scp=0022596780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022596780&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 393

EP - 403

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 3

ER -